Compare Lemonade Inc (LMND) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Lemonade Inc trades at $51.73 (market cap $4.09B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.
| LMND | XBI | |
|---|---|---|
Market Cap | $4.09B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $96.57 | $164.28 |
52-Week Low | $47.38 | $86.92 |
Enterprise Value | $3.95B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $51.63, down 1.99% on the day, with a bearish technical signal from moving averages. Revenue growth is strong, reaching $737.9M in 2025, but the company remains unprofitable with a net income margin of -14.19%. Recent Q2 2026 earnings beat expectations, and the company targets positive adjusted EBITDA by Q4 2026, yet the stock faces selling pressure amid valuation concerns.
The outlook hinges on Lemonade's path to profitability; achieving its EBITDA target could drive upside toward the $58 consensus price target. Key risks include persistent losses, competitive pressures, and execution challenges in scaling its AI-driven insurance model. Investor sentiment is divided, reflecting the high-growth but high-burn profile.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
